Provided by Tiger Trade Technology Pte. Ltd.

Pacific Biosciences of California

1.27
-0.0200-1.55%
Post-market: 1.270.0016+0.13%19:43 EDT
Volume:4.71M
Turnover:6.01M
Market Cap:394.32M
PE:-2.95
High:1.31
Open:1.26
Low:1.25
Close:1.29
52wk High:2.73
52wk Low:1.07
Shares:310.49M
Float Shares:302.00M
Volume Ratio:1.07
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4310
EPS(LYR):-1.8215
ROE:-929.32%
ROA:-14.07%
PB:-11.87
PE(LYR):-0.70

Loading ...

PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system

GlobeNewswire
·
Aug 05

Pacific Biosciences of California Inc Expected to Post a Loss of 13 Cents a Share - Earnings Preview

Reuters
·
Aug 04

PacBio to Join Canaccord Genuity Growth Conference Fireside Chat

Reuters
·
Jul 29

Pacbio Schedules Conference Call for Second-quarter 2026 Results

Reuters
·
Jul 16

PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026

GlobeNewswire
·
Jul 16

Pacbio Director Christopher Smith Resigns from Board

Reuters
·
Jul 10

Pacific Biosciences holds annual shareholder meeting

Reuters
·
Jun 05

PacBio announces SPRQ-Nx chemistry now shipping worldwide

TIPRANKS
·
May 26

PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing

GlobeNewswire
·
May 26

PacBio joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 22

PacBio collaborates with Blank Bio on long-read bulk RNA-seq for oncology models

Reuters
·
May 19

Pacific Biosciences Is Maintained at Underweight by Barclays

Dow Jones
·
May 11

PacBio HiFi genome sequencing study flags genetic findings in 1-in-10 subfertility couples

Reuters
·
May 11

HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss

GlobeNewswire
·
May 11

PacBio price target raised to $1.50 from $1 at Barclays

TIPRANKS
·
May 11

Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF), Astrana Health (ASTH) and Pacific Biosciences (PACB)

TIPRANKS
·
May 11

Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures

Dow Jones
·
May 09

PacBio sees FY26 revenue $165M-$175M, consensus $174.42M

TIPRANKS
·
May 08

DNA sequencing systems co PacBio Q1 adjusted loss narrows

Reuters
·
May 08

PacBio Q1 FY26 GAAP net loss narrows to $8.3 million; revenue flat at $37.2 million

Reuters
·
May 08